See more : Five Below, Inc. (0IPD.L) Income Statement Analysis – Financial Results
Complete financial analysis of ICON Public Limited Company (ICLR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICON Public Limited Company, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- DiamondRock Hospitality Company (DRH-PA) Income Statement Analysis – Financial Results
- Hitachi Energy India Limited (POWERINDIA.NS) Income Statement Analysis – Financial Results
- Axel Mark Inc. (3624.T) Income Statement Analysis – Financial Results
- DCM Corp. (024090.KS) Income Statement Analysis – Financial Results
- Barinthus Biotherapeutics plc (BRNS) Income Statement Analysis – Financial Results
ICON Public Limited Company (ICLR)
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.12B | 7.74B | 5.48B | 2.80B | 2.81B | 2.60B | 1.76B | 1.67B | 1.57B | 1.50B | 1.34B | 1.12B | 945.73M | 900.04M | 887.61M | 865.25M | 630.72M | 455.60M | 0.00 | 296.92M | 225.73M | 156.56M | 116.16M | 80.77M | 55.80M | 42.10M |
| Cost of Revenue | 5.72B | 5.53B | 3.97B | 1.99B | 1.97B | 1.83B | 1.03B | 961.33M | 908.98M | 903.17M | 845.41M | 718.13M | 611.92M | 541.39M | 507.78M | 489.24M | 354.48M | 256.26M | 0.00 | 162.56M | 122.37M | 83.37M | 63.80M | 42.04M | 29.30M | 0.00 |
| Gross Profit | 2.40B | 2.21B | 1.51B | 808.03M | 831.70M | 769.49M | 726.96M | 705.15M | 666.00M | 600.15M | 490.65M | 396.87M | 333.81M | 358.66M | 379.83M | 376.01M | 276.24M | 199.33M | 0.00 | 134.36M | 103.35M | 73.18M | 52.36M | 38.72M | 26.50M | 42.10M |
| Gross Profit Ratio | 29.56% | 28.60% | 27.52% | 28.89% | 29.64% | 29.64% | 41.34% | 42.31% | 42.29% | 39.92% | 36.72% | 35.59% | 35.30% | 39.85% | 42.79% | 43.46% | 43.80% | 43.75% | 0.00% | 45.25% | 45.79% | 46.75% | 45.08% | 47.94% | 47.49% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 319.28M | 317.00M | 318.56M | 322.27M | 332.90M | 308.74M | 277.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 6.74M | 7.17M | 4.51M | 3.56M | 5.20M | 3.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 776.36M | 778.75M | 585.33M | 341.69M | 336.75M | 325.79M | 323.74M | 325.73M | 326.79M | 336.46M | 313.93M | 280.78M | 255.86M | 232.69M | 230.91M | 248.78M | 187.99M | 136.57M | 0.00 | 88.81M | 71.12M | 48.95M | 36.31M | 27.35M | 18.00M | 0.00 |
| Other Expenses | 667.72M | 569.51M | 314.99M | 74.38M | 61.55M | 65.92M | 61.30M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 41.47M | 27.73M | 19.01M | 14.95M | 0.00 | 11.17M | 7.31M | 6.02M | 4.98M | 3.23M | 2.00M | 0.00 |
| Operating Expenses | 1.44B | 1.35B | 900.32M | 416.07M | 398.30M | 392.37M | 395.02M | 385.30M | 384.46M | 389.00M | 360.45M | 327.30M | 294.55M | 266.56M | 272.38M | 276.51M | 207.00M | 151.52M | 0.00 | 99.98M | 78.42M | 54.97M | 41.29M | 30.58M | 20.00M | 0.00 |
| Cost & Expenses | 7.16B | 6.88B | 4.87B | 2.41B | 2.37B | 2.22B | 1.43B | 1.35B | 1.29B | 1.29B | 1.21B | 1.05B | 906.47M | 807.95M | 780.16M | 765.74M | 561.48M | 407.78M | 0.00 | 262.54M | 200.80M | 138.34M | 105.09M | 72.62M | 49.30M | 0.00 |
| Interest Income | 5.01M | 2.35M | 574.00K | 2.72M | 6.86M | 4.76M | 2.35M | 1.48M | 1.31M | 1.15M | 986.00K | 1.15M | 1.19M | 1.76M | 752.00K | 2.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 336.70M | 229.73M | 182.42M | 15.07M | 6.42M | 13.61M | 12.99M | 13.01M | 3.99M | 785.00K | 1.29M | 1.97M | 1.64M | 1.13M | 3.53M | 4.11M | 0.00 | 0.00 | 0.00 | 281.00K | 0.00 | 0.00 | 0.00 | 575.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 585.95M | 614.73M | 360.33M | 94.61M | 91.92M | 65.92M | 61.25M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 32.66M | 27.73M | 18.89M | 14.84M | 0.00 | 10.60M | 7.27M | 5.97M | 4.96M | 3.23M | 2.00M | 0.00 |
| EBITDA | 1.52B | 1.41B | 739.43M | 488.83M | 532.19M | 451.76M | 401.94M | 379.43M | 339.21M | 263.69M | 168.67M | 111.09M | 69.32M | 127.73M | 140.86M | 130.11M | 88.25M | 62.77M | 0.00 | 31.94M | 45.55M | 32.23M | 24.23M | 16.05M | 8.50M | 42.10M |
| EBITDA Ratio | 18.74% | 18.57% | 16.85% | 17.48% | 17.64% | 17.22% | 19.33% | 23.26% | 21.54% | 18.13% | 13.90% | 10.18% | 9.28% | 14.00% | 15.87% | 15.04% | 13.99% | 13.78% | 0.00% | 15.34% | 14.28% | 15.48% | 13.82% | 16.09% | 15.23% | 100.00% |
| Operating Income | 956.15M | 795.24M | 608.47M | 391.97M | 433.41M | 377.12M | 331.95M | 311.69M | 281.54M | 202.35M | 121.17M | 69.57M | 29.44M | 92.10M | 107.45M | 99.50M | 69.24M | 47.82M | 0.00 | 34.38M | 24.93M | 18.21M | 11.08M | 8.15M | 6.50M | 42.10M |
| Operating Income Ratio | 11.78% | 10.27% | 11.10% | 14.01% | 15.45% | 14.53% | 18.88% | 18.70% | 17.88% | 13.46% | 9.07% | 6.24% | 3.11% | 10.23% | 12.11% | 11.50% | 10.98% | 10.50% | 0.00% | 11.58% | 11.04% | 11.63% | 9.53% | 10.09% | 11.65% | 100.00% |
| Total Other Income/Expenses | -331.69M | -227.39M | -181.85M | -10.30M | -6.42M | -8.74M | -10.28M | -11.52M | -2.69M | 366.00K | -302.00K | -796.00K | -448.00K | 629.00K | -2.78M | -1.22M | 2.74M | 3.64M | 0.00 | 979.00K | -9.10M | -5.60M | -4.62M | 2.52M | 2.60M | -32.49M |
| Income Before Tax | 624.47M | 567.85M | 196.68M | 382.18M | 426.99M | 368.38M | 327.67M | 300.17M | 278.85M | 202.72M | 120.87M | 68.70M | 29.00M | 92.72M | 104.67M | 98.28M | 71.98M | 51.46M | 0.00 | 34.67M | 25.28M | 19.33M | 13.60M | 9.19M | 9.10M | 0.00 |
| Income Before Tax Ratio | 7.69% | 7.34% | 3.59% | 13.66% | 15.22% | 14.19% | 18.63% | 18.01% | 17.71% | 13.48% | 9.05% | 6.16% | 3.07% | 10.30% | 11.79% | 11.36% | 11.41% | 11.29% | 0.00% | 11.68% | 11.20% | 12.35% | 11.70% | 11.38% | 16.31% | 0.00% |
| Income Tax Expense | 11.75M | 59.41M | 41.33M | 50.75M | 51.13M | 45.56M | 54.72M | 37.99M | 39.31M | 30.25M | 18.05M | 10.36M | 6.12M | 5.65M | 10.38M | 19.97M | 15.83M | 12.92M | 0.00 | 8.93M | 7.00M | 5.13M | 2.62M | 3.12M | 1.60M | 38.20M |
| Net Income | 612.34M | 505.30M | 153.19M | 327.81M | 373.99M | 322.82M | 272.94M | 262.18M | 239.54M | 172.47M | 102.81M | 58.35M | 22.88M | 87.07M | 94.30M | 78.12M | 55.96M | 38.30M | 0.00 | 25.74M | 18.28M | 14.20M | 10.98M | 6.07M | 7.50M | 3.90M |
| Net Income Ratio | 7.54% | 6.53% | 2.79% | 11.72% | 13.33% | 12.44% | 15.52% | 15.73% | 15.21% | 11.47% | 7.70% | 5.23% | 2.42% | 9.67% | 10.62% | 9.03% | 8.87% | 8.41% | 0.00% | 8.67% | 8.10% | 9.07% | 9.45% | 7.51% | 13.44% | 9.26% |
| EPS | 7.46 | 6.20 | 2.28 | 6.29 | 6.94 | 5.96 | 5.04 | 4.75 | 4.08 | 2.80 | 1.69 | 0.97 | 0.38 | 1.46 | 1.61 | 1.34 | 1.95 | 1.35 | 0.00 | 1.94 | 1.55 | 1.22 | 0.97 | 0.55 | 0.69 | 0.28 |
| EPS Diluted | 7.40 | 6.13 | 2.25 | 6.24 | 6.88 | 5.90 | 4.98 | 4.65 | 3.97 | 2.73 | 1.65 | 0.96 | 0.37 | 1.44 | 1.57 | 1.30 | 1.88 | 1.33 | 0.00 | 1.88 | 1.50 | 1.16 | 0.92 | 0.51 | 0.63 | 0.25 |
| Weighted Avg Shares Out | 82.10M | 81.53M | 67.11M | 52.86M | 53.86M | 54.12M | 54.13M | 55.25M | 58.75M | 61.50M | 60.91M | 59.97M | 60.38M | 59.72M | 58.64M | 58.25M | 28.71M | 28.31M | 13.86M | 13.27M | 11.81M | 11.66M | 11.29M | 11.05M | 10.91M | 13.93M |
| Weighted Avg Shares Out (Dil) | 82.72M | 82.47M | 68.07M | 53.28M | 54.33M | 54.74M | 54.87M | 56.41M | 60.29M | 63.13M | 62.25M | 60.68M | 61.07M | 60.64M | 59.90M | 60.22M | 29.75M | 28.86M | 13.86M | 13.70M | 12.18M | 12.24M | 11.94M | 11.82M | 11.92M | 15.92M |
ICON Public Limited Company Being Investigated on Behalf of ICON Public Limited Company Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Shareholders that Lost Money on ICON Public Limited Company (ICLR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - ICLR
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
Shareholder Rights Advocates at Levi & Korsinsky Investigate ICON Public Limited Company (ICLR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October...
ICON Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely...
eXp Realty Unveils Game-Changing ICON and Revenue Share Capping Incentive Programs at eXpcon Miami
New initiatives designed to supercharge agent growth and unlock unprecedented earning potential New initiatives designed to supercharge agent growth and unlock unprecedented earning potential
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.
ICON Public Limited Company (ICLR) Q3 2024 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Kate Haven - Vice President of Investor Relations Steve Cutler - Chief Executive Officer Brendan Brennan - Chief Financial Officer Conference...
Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates
Icon PLC (ICLR) came out with quarterly earnings of $3.35 per share, missing the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.30 per share a year ago.
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Trading 3.72% Higher on Oct 2
Shares of Icon PLC (ICLR, Financial) surged 3.72% in mid-day trading on Oct 2. The stock reached an intraday high of $295.09, up from its previous close of $284.51.
Source: https://incomestatements.info
Category: Stock Reports